RxDoctor Payments DataLook up a doctor →

Levent Akduman, MD

Ophthalmology · St Louis, MONPI 1245344605

Payments from drug & device makers

$46,795in general payments, 2019–2025

Across 236 payments — averaging $198.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$33K
  • Astellas Pharma US Inc$4K
  • ANI Pharmaceuticals, Inc.$3K
  • Alimera Sciences, Inc.$1K
  • Alcon$1K
  • Genentech USA, Inc.$935
  • plus $5K from 18 others

What the payments were for

  • Consulting fees$3,0006%
  • Speaking & faculty fees$32,80070%
  • Travel & lodging$5151%
  • Food & beverage$10,48022%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$46,795 in reported general payments places this provider in the 85th percentile of 286 ophthalmology providers in Missouri.

See all ophthalmology providers in Missouri

Medicare billing

Part B allowed, 2024
$4,105,535
Medicare patients
1,278
Services billed
30,306

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Tobramycin-DexamethasoneTobramycin/Dexamethasone343$15,098
LumiganBimatoprost19$6,678
Prednisolone Acetate152$6,547
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol23$3,826
Brimonidine Tartrate90$3,739
Tobradex StTobramycin/Dexamethasone14$3,265
Latanoprost237$3,055
ValacyclovirValacyclovir Hcl13$2,021
Dorzolamide Hcl101$1,611
Timolol Maleate129$1,265
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat54$528
Ketorolac Tromethamine21$417
Ofloxacin13$179

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan$32,718$6,67819 claims
Eyevance Pharmaceuticals LLCTobradex St$224$3,26514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 286 ophthalmology providers in Missouri.

Other ophthalmology in St Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →